All references below are clickable: clicking will take you directly to the study

  1. Chan, K.H., et al., Epstein-Barr virus (EBV) DNA in sera of patients with primary EBV infection. J Clin Microbiol, 2001. 39(11): p. 4152-4.
  2. Cohen, J. I. (2009). Optimal treatment for chronic active Epstein-Barr virus disease. Pediatr Transplant, 13(4), 393-396. doi:10.1111/j.1399-3046.2008.01095.x
  3. EBV abtibody profile. Newfoundland and Labrador Public Health Laboratory, a Division of Eastern Health.
  4. Eligio, P., Delia, R., & Valeria, G. (2010). EBV Chronic Infections. Mediterr J Hematol Infect Dis, 2(1), e2010022. doi:10.4084/MJHID.2010.022
  5. Epstein-Barr virus (EBV) antibody profile, serum. 2017 [cited 2017 March 03]; Available from:
  6. Gartner, B. Euroline EBV profile 2 (IgG/IgM). 2010 [cited 2017 July 2]
  7. Janegova, A., Janega, P., Rychly, B., Kuracinova, K., & Babal, P. (2015). The role of Epstein-Barr virus infection in the development of autoimmune thyroid diseases. Endokrynol Pol, 66(2), 132-136. doi:10.5603/EP.2015.0020 
  8. Luderer, R., et al., Real-time Epstein-Barr virus PCR for the diagnosis of primary EBV infections and EBV reactivation. Mol Diagn, 2005. 9(4): p. 195-200.
  9. McGeoch, D. J., Cook, S., Dolan, A., Jamieson, F. E., & Telford, E. A. (1995). Molecular phylogeny and evolutionary timescale for the family of mammalian herpesviruses. J Mol Biol, 247(3), 443-458. doi:10.1006/jmbi.1995.0152
  10. Okano, M., Kawa, K., Kimura, H., Yachie, A., Wakiguchi, H., Maeda, A., . . . Imashuku, S. (2005). Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol, 80(1), 64-69. doi:10.1002/ajh.20398
  11. Pratesi, F., Tommasi, C., Anzilotti, C., Puxeddu, I., Sardano, E., Di Colo, G., & Migliorini, P. (2011). Antibodies to a new viral citrullinated peptide, VCP2: fine specificity and correlation with anti-cyclic citrullinated peptide (CCP) and anti-VCP1 antibodies. Clin Exp Immunol, 164(3), 337-345. doi:10.1111/j.1365-2249.2011.04378.x